



Schedule 3 – Information on Management Positions

Nils Brüner

Proposed Member of the Board of Directors in Scandion Oncology A/S from October 28, 2022.

Education: MD, DMSC, University of Copenhagen. Additional education in molecular cell biology, National Cancer Institute, NIH, USA.

Background: Have worked for 15 years in Oncology and Internal Medicine at hospitals in Copenhagen. Have worked in USA, at the National Cancer Institute, NIH and at Georgetown University, Washington DC. 1994-2002, Associate Professor (overlæge) at Finsen Centret, Rigshospitalet, Copenhagen. 2002-2018, Professor, University of Copenhagen

2006-2009 Chairman for Translational Cancer Research at European Organization for Research and Treatment of Cancer (EORTC) and at the same time member of the Board of Directors of EORTC. 2009-2015 head of Sino-Danish Breast Cancer Center (Grundforskningscenter).

2013- 2018 Head, Unit for Translational Cancer Research, Danish Cancer Society

Published more than 370 scientific papers in peer-reviewed international Journals.

Co-founder of Oncology Venture and Scandion Oncology. From 2018 – 2020, CEO at Scandion Oncology.

Other ongoing assignments: BoD member of 2CureX, Gibson Oncology and GeneTelligence.

Independence: Independent in relation to both the Company and executive management as well as larger shareholders.

Scandion Oncology shares: Holds 266.551 shares